Characterization of T-Cell Receptor Repertoire in Patients with Rheumatoid Arthritis Receiving Biologic Therapies

<div>Correlation between TCRB repertoire diversity and disease activity in bDMARD-treated RA patients. The TCRB repertoire diversity showed a negative trend toward DAS28, CDAI, and SDAI scores (a) in all bDMARD-treated RA patients, (b) in patients receiving adalimumab followed by rituximab, and (c) in patients receiving adalimumab followed by tocilizumab. The statistical analysis was performed using the Pearson correlation.</div>

Disease Markers

fig5

Figure 5

Figure 5: Characterization of T-Cell Receptor Repertoire in Patients with Rheumatoid Arthritis Receiving Biologic Therapies 